Vimarsana
Biggest News Aggregation in the World

Page 30 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences - Vimarsana News

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline,...

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021 - Vimarsana News

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused…

UPDATE: Sio Gene Therapies to Present New Data at the - Vimarsana News

UPDATE: Sio Gene Therapies to Present New Data at the

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1...

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference - Vimarsana News

Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference

/PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases,...

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021 - Vimarsana News

Compugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that...